Zobrazeno 1 - 10
of 231
pro vyhledávání: '"miR-675"'
Autor:
He Zhang, Fei Wang, Xiangsheng Pang, Yue Zhou, Shiming Li, Wenjiong Li, Peng Zhang, Xiaoping Chen
Publikováno v:
Molecular Medicine, Vol 29, Iss 1, Pp 1-12 (2023)
Abstract Background Long non-coding RNA (lncRNA) H19 is one of the most highly expressed and conserved transcripts in mammalian development, and its functions have been fully discussed in many contexts including tumorigenesis and skeletal muscle deve
Externí odkaz:
https://doaj.org/article/9462105c2fa9489db1d7466e8b94801f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Shimaa Abdelsattar, Dina Sweed, Hala F. M. Kamel, Zeinab A. Kasemy, Abdallah M. Gameel, Hassan Elzohry, Omnia Ameen, Eman Ibrahim Elgizawy, Ahmed Sallam, Asmaa Mosbeh, Mahmoud S. Abdallah, Fatma O. Khalil, Hiba S. Al-Amodi, Sally M. El-Hefnway
Publikováno v:
Biomolecules, Vol 13, Iss 1, p 3 (2022)
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Interestingly, lncRNA-H19 acts independently in HCC and influences miR-675 expressions. We aimed to assess the potential utility of tissue lncRNA-H19 versus miR-675 expressio
Externí odkaz:
https://doaj.org/article/e4e383a70f08448a85a3197878ac7d84
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jin Yan, Yifeng Zhang, Qiang She, Xuan Li, Lei Peng, Xiaoyong Wang, Shiyu Liu, Xiaoran Shen, Weifeng Zhang, Yu Dong, Jieyu Lu, Guoxin Zhang
Publikováno v:
Cellular Physiology and Biochemistry, Vol 42, Iss 6, Pp 2364-2376 (2017)
Background: Long noncoding RNA (lncRNA) H19 is emerging as a vital regulatory molecule in the progression of different types of cancer and miR-675 is reported to be embedded in H19's first exon. However, their function and specific mechanisms of acti
Externí odkaz:
https://doaj.org/article/87d83f56057c45068349032f5314d8c1
Autor:
Christina S. Schultheiss, Stephan Laggai, Beate Czepukojc, Usama K. Hussein, Markus List, Ahmad Barghash, Sascha Tierling, Kevan Hosseini, Nicole Golob-Schwarzl, Juliane Pokorny, Nina Hachenthal, Marcel Schulz, Volkhard Helms, Jörn Walter, Vincent Zimmer, Frank Lammert, Rainer M. Bohle, Luisa Dandolo, Johannes Haybaeck, Alexandra K. Kiemer, Sonja M. Kessler
Publikováno v:
Cell Stress, Vol 1, Iss 1, Pp 37-54 (2017)
The long non-coding RNA (lncRNA) H19 represents a maternally expressed and epigenetically regulated imprinted gene product and is discussed to have either tumor-promoting or tumor-suppressive actions. Recently, H19 was shown to be regulated under inf
Externí odkaz:
https://doaj.org/article/45eb03241ccc4a4c99e499408cff01fa
Autor:
Laura Saieva, Maria Magdalena Barreca, Chiara Zichittella, Maria Giulia Prado, Marco Tripodi, Riccardo Alessandro, Alice Conigliaro
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 11, p 3832 (2020)
The reduction of oxygen partial pressure in growing tumors triggers numerous survival strategies driven by the transcription factor complex HIF1 (Hypoxia Inducible Factor-1). Recent evidence revealed that HIF1 promotes rapid and effective phenotypic
Externí odkaz:
https://doaj.org/article/dcc5690de2914efb8eb896bf8782aa50
Publikováno v:
Bioengineered, Vol 12, Iss 1, Pp 5305-5322 (2021)
Bioengineered
article-version (VoR) Version of Record
Bioengineered
article-version (VoR) Version of Record
Early growth response-1 (EGR1) is a multi-domain protein and an immediate early transcription factor that is induced during liver injury and controls the expression of a variety of genes implicated in metabolism, cell proliferation, and tumorigenesis
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jiayan Mao, Zhenrong Li, Xiqing Li, Wei Chen, Hao Li, Lei Yan, Yanhui Liu, Yongzi Xu, Fei Xue, Jian Shen
Publikováno v:
Oncology Reports
Sorafenib is the first‑line treatment for advanced hepatocellular carcinoma (HCC). Since many HCC patients experience drug resistance, there is an urgent need to discover more effective therapeutic strategies to overcome drug resistance. Long non